The tweet was deleted by the author.
But we saved everything 🙂.
Merck has announced the release of long-term follow-up data regarding their immunotherapy option for non-small cell lung cancer patients. This information was shared at the European Society for Medical Oncology (ESMO), targeting individuals with early and advanced stages.
The data showcases the effectiveness and durability of Merck's immunotherapy, which represents a significant step forward in treating this type of cancer. The company remains committed to advancing cancer treatment through research and innovative solutions.